Affymax, Inc.
US ˙ OTCPK

Introduktion

Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Ted W Love. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.

Gennemsnitlig handelsrentabilitet

Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.

Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.

Opdateringsfrekvens: Dagligt

Se listen over de mest profitable insiderhandlere.

Virksomheder med rapporterede insider-stillinger

SEC-registreringen viser, at Ted W Love har rapporteret besiddelser eller handler i følgende virksomheder:

Sikkerhed Titel Senest indberettede beholdninger
US:RPRX / Royalty Pharma plc Director 53.848
US:GILD / Gilead Sciences, Inc. Director 4.338
US:SGEN / Seagen Inc Director 0
US:GBT / Global Blood Therapeutics Inc. President and CEO, Director 0
Director 0
US:FOLD / Amicus Therapeutics, Inc. Director 18.574
US:CASC / Cascadian Therapeutics, Inc. Director 0
US:KBIO / KaloBios Pharmaceuticals, Inc. Director 5.000
US:SNTS / Santarus, Inc Director 0
US:MSTX / Tidal Trust II - Defiance Daily Target 2X Long MSTR ETF Director 62.451
US:ONXX / Onyx Pharmaceuticals Inc EVP, R&D and Tech. Operations 77.756
US:AFFY / Affymax, Inc. Director 12.000
US:ABIO / ARCA biopharma, Inc. Director 7.500
Sådan fortolkes diagrammerne

Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Ted W Love. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.

I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.

Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.

Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.

Insiderkøb AFFY / Affymax, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AFFY / Affymax, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

AFFY / Affymax, Inc. Insider Trades
Insidersalg AFFY / Affymax, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AFFY / Affymax, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

AFFY / Affymax, Inc. Insider Trades
Insiderkøb FOLD / Amicus Therapeutics, Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AFFY / Affymax, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

FOLD / Amicus Therapeutics, Inc. Insider Trades
Insidersalg FOLD / Amicus Therapeutics, Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AFFY / Affymax, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

FOLD / Amicus Therapeutics, Inc. Insider Trades
Insiderkøb MSTX / Tidal Trust II - Defiance Daily Target 2X Long MSTR ETF – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AFFY / Affymax, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

MSTX / Tidal Trust II - Defiance Daily Target 2X Long MSTR ETF Insider Trades
Insidersalg MSTX / Tidal Trust II - Defiance Daily Target 2X Long MSTR ETF – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AFFY / Affymax, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

MSTX / Tidal Trust II - Defiance Daily Target 2X Long MSTR ETF Insider Trades
Insiderkøb RPRX / Royalty Pharma plc – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i AFFY / Affymax, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

RPRX / Royalty Pharma plc Insider Trades
Insidersalg RPRX / Royalty Pharma plc – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i AFFY / Affymax, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

RPRX / Royalty Pharma plc Insider Trades
Insiderhandelshistorie

Denne tabel viser den komplette liste over insiderhandler foretaget af Ted W Love som oplyst til Securities Exchange Commission (SEC).

Fil dato Transdato Form Ticker Sikkerhed Kode 10b5-1 Aktier Resterende aktier Procent
Lave om
Del
Pris
Tran
Værdi
Tilbage
Værdi
2025-05-14 2025-05-13 4 RPRX Royalty Pharma plc
Class A Ordinary Shares
A - Award 7.614 53.848 16,47
2025-05-08 2025-05-07 4 GILD GILEAD SCIENCES, INC.
Common Stock
A - Award 1.516 4.338 53,72
2024-06-10 2024-06-07 4 RPRX Royalty Pharma plc
Class A Ordinary Shares
A - Award 9.293 46.234 25,16
2024-05-09 2024-05-08 4 GILD GILEAD SCIENCES, INC.
Common Stock
A - Award 2.310 2.822 451,17
2024-02-06 2024-02-02 4 GILD GILEAD SCIENCES, INC.
Common Stock
A - Award 512 512
2023-12-15 2023-12-14 4 SGEN Seagen Inc.
Common Stock
D - Sale to Issuer -4.255 0 -100,00 229,00 -974.395
2023-06-26 2023-06-23 4 RPRX Royalty Pharma plc
Class A Ordinary Shares
A - Award 7.747 36.941 26,54
2023-06-02 2023-05-31 4 SGEN Seagen Inc.
Common Stock
A - Award 2.044 6.748 43,45
2022-10-06 2022-10-05 4 GBT Global Blood Therapeutics, Inc.
Common Stock
D - Sale to Issuer -2.500 0 -100,00
2022-10-06 2022-10-05 4 GBT Global Blood Therapeutics, Inc.
Common Stock
D - Sale to Issuer -2.500 0 -100,00
2022-10-06 2022-10-05 4 GBT Global Blood Therapeutics, Inc.
Common Stock
D - Sale to Issuer -102.000 0 -100,00
2022-10-06 2022-10-05 4 GBT Global Blood Therapeutics, Inc.
Common Stock
D - Sale to Issuer -119.650 0 -100,00
2022-10-06 2022-10-05 4 GBT Global Blood Therapeutics, Inc.
Common Stock
D - Sale to Issuer -119.650 0 -100,00
2022-10-06 2022-10-05 4 GBT Global Blood Therapeutics, Inc.
Common Stock
D - Sale to Issuer -576.318 0 -100,00
2022-09-29 2022-09-27 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 18.291 576.318 3,28 16,40 299.972 9.451.615
2022-09-29 2022-09-13 4 GBT Global Blood Therapeutics, Inc.
Common Stock
G - Gift 17.650 119.650 17,30
2022-09-29 2022-09-13 4 GBT Global Blood Therapeutics, Inc.
Common Stock
G - Gift 17.650 119.650 17,30
2022-09-29 2022-09-13 4 GBT Global Blood Therapeutics, Inc.
Common Stock
G - Gift -35.300 558.027 -5,95
2022-09-29 2022-09-09 4 GBT Global Blood Therapeutics, Inc.
Common Stock
G - Gift -221.200 593.327 -27,16
2022-09-06 2022-09-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
F - Taxes -9.200 814.527 -1,12 68,15 -626.980 55.510.015
2022-09-06 2022-09-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 9.109 823.727 1,12
2022-09-06 2022-09-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 9.444 814.618 1,17
2022-08-03 2022-08-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
F - Taxes -10.018 805.174 -1,23 32,40 -324.583 26.087.638
2022-08-03 2022-08-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 20.205 815.192 2,54
2022-06-24 2022-06-24 4 RPRX Royalty Pharma plc
Class A Ordinary Shares
A - Award 6.328 29.194 27,67
2022-05-17 2022-05-13 4 SGEN Seagen Inc.
Non-Qualified Stock Option (right to buy)
A - Award 3.676 3.676
2022-05-17 2022-05-13 4 SGEN Seagen Inc.
Common Stock
A - Award 1.503 4.704 46,95
2022-03-03 2022-03-01 4 GBT Global Blood Therapeutics, Inc.
Stock Option (Right to buy)
A - Award 118.090 118.090
2022-03-03 2022-03-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
A - Award 72.877 72.877
2022-03-03 2022-03-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
A - Award 72.877 72.877
2022-03-03 2022-03-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -9.445 56.667 -14,29
2022-03-03 2022-03-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
F - Taxes -4.074 794.987 -0,51 29,87 -121.690 23.746.262
2022-03-03 2022-03-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 9.445 799.061 1,20
2022-03-03 2022-02-28 4 GBT Global Blood Therapeutics, Inc.
Common Stock
A - Award 839 789.616 0,11 25,37 21.285 20.032.558
2022-02-03 2022-02-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -8.955 35.820 -20,00
2022-02-03 2022-02-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -11.250 22.500 -33,33
2022-02-03 2022-02-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -9.750 0 -100,00
2022-02-03 2022-02-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
F - Taxes -10.531 788.777 -1,32 29,33 -308.874 23.134.829
2022-02-03 2022-02-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 29.955 799.308 3,89
2022-01-06 2016-07-01 4/A GBT Global Blood Therapeutics, Inc.
Common Stock
D - Sale to Issuer -24.821 1.117.815 -2,17 3,40 -84.391 3.800.571
2021-09-24 2021-08-01 4/A GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -8.955 44.775 -16,67
2021-09-24 2021-08-01 4/A GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -11.250 33.750 -25,00
2021-09-24 2021-08-01 4/A GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -9.750 9.750 -50,00
2021-09-24 2021-08-01 4/A GBT Global Blood Therapeutics, Inc.
Common Stock
F - Taxes -14.853 789.413 -1,85 27,33 -405.932 21.574.657
2021-09-24 2021-08-01 4/A GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 29.955 804.266 3,87
2021-09-03 2021-09-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -9.444 66.112 -12,50
2021-09-03 2021-09-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
F - Taxes -4.683 794.174 -0,59 29,85 -139.788 23.706.094
2021-09-03 2021-09-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 9.444 798.857 1,20
2021-08-03 2021-08-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -8.955 44.775 -16,67
2021-08-03 2021-08-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -11.250 33.750 -25,00
2021-08-03 2021-08-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -9.750 9.750 -50,00
2021-08-03 2021-08-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
F - Taxes -14.853 789.413 -1,85 27,33 -405.932 21.574.657
2021-08-03 2021-08-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 29.955 804.266 3,87
2021-06-29 2021-06-25 4 RPRX Royalty Pharma plc
Class A Ordinary Shares
A - Award 5.726 22.866 33,41
2021-05-18 2021-05-14 4 SGEN Seagen Inc.
Non-Qualified Stock Option (right to buy)
A - Award 3.462 3.462
2021-05-18 2021-05-14 4 SGEN Seagen Inc.
Common Stock
A - Award 1.402 3.201 77,93
2021-03-03 2021-03-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
A - Award 75.556 75.556
2021-03-03 2021-03-01 4 GBT Global Blood Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 132.433 132.433
2021-03-03 2021-02-28 4 GBT Global Blood Therapeutics, Inc.
Common Stock
A - Award 370 774.311 0,05 36,21 13.398 28.037.801
2021-02-03 2021-02-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -8.955 53.730 -14,29
2021-02-03 2021-02-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -11.250 45.000 -20,00
2021-02-03 2021-02-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -9.750 19.500 -33,33
2021-02-03 2021-02-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -12.063 0 -100,00
2021-02-03 2021-02-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
F - Taxes -17.893 773.941 -2,26 49,49 -885.525 38.302.340
2021-02-03 2021-02-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 42.018 791.834 5,60
2020-08-18 2020-08-17 4 SGEN SEATTLE GENETICS INC /WA
Non-Qualified Stock Option (right to buy)
A - Award 4.460 4.460
2020-08-18 2020-08-17 4 SGEN SEATTLE GENETICS INC /WA
Common Stock
A - Award 1.799 1.799
2020-08-17 2020-08-13 4 RPRX Royalty Pharma plc
Class A Ordinary Shares
A - Award 7.280 17.280 72,80
2020-08-10 3 RPRX Royalty Pharma plc
Class A Ordinary Shares
20.000
2020-08-10 3 RPRX Royalty Pharma plc
Class A Ordinary Shares
20.000
2020-08-10 3 RPRX Royalty Pharma plc
Class A Ordinary Shares
20.000
2020-08-04 2020-08-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -8.955 62.685 -12,50
2020-08-04 2020-08-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -11.250 56.250 -16,67
2020-08-04 2020-08-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -9.750 29.250 -25,00
2020-08-04 2020-08-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -12.062 12.063 -50,00
2020-08-04 2020-08-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
F - Taxes -20.834 749.816 -2,70 67,48 -1.405.878 50.597.584
2020-08-04 2020-08-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 42.017 770.650 5,77
2020-08-04 2020-06-12 4 GBT Global Blood Therapeutics, Inc.
Common Stock
G - Gift -306.000 728.633 -29,58
2020-07-02 2020-07-02 4 PTLA PORTOLA PHARMACEUTICALS INC
Stock Option (Right to Buy)
D - Sale to Issuer -14.812 0 -100,00
2020-07-02 2020-07-02 4 PTLA PORTOLA PHARMACEUTICALS INC
Stock Option (Right to Buy)
D - Sale to Issuer -11.377 0 -100,00 0,06 -683
2020-07-02 2020-07-02 4 PTLA PORTOLA PHARMACEUTICALS INC
Restricted Stock Units
D - Sale to Issuer -15.575 0 -100,00 18,00 -280.350
2020-06-15 2020-06-12 4 PTLA PORTOLA PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 11.377 11.377
2020-06-15 2020-06-12 4 PTLA PORTOLA PHARMACEUTICALS INC
Common Stock
A - Award 7.281 15.575 87,79
2020-06-08 2020-06-04 4 FOLD AMICUS THERAPEUTICS, INC.
Stock Options (right to buy)
A - Award 18.574 18.574
2020-06-08 2020-06-04 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
A - Award 5.855 131.000 4,68
2020-06-03 2020-06-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
A - Award 141.400 141.400
2020-04-29 2020-04-28 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale X -40.000 1.034.633 -3,72 80,00 -3.200.160 82.774.779
2020-04-29 2020-04-27 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale X -1.517 1.074.633 -0,14 80,63 -122.320 86.650.560
2020-04-29 2020-04-27 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale X -1.300 1.076.150 -0,12 81,15 -105.494 87.328.712
2020-02-20 2020-02-18 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale X -1.818 1.077.450 -0,17 70,92 -128.940 76.416.956
2020-02-20 2020-02-18 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale X -2.189 1.079.268 -0,20 70,22 -153.721 75.790.732
2020-02-04 2020-02-03 4 GBT Global Blood Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 114.190 114.190
2020-02-04 2020-02-03 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
A - Award 71.640 71.640
2020-02-04 2020-02-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -11.250 67.500 -14,29
2020-02-04 2020-02-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -9.750 39.000 -20,00
2020-02-04 2020-02-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -12.063 24.125 -33,33
2020-02-04 2020-02-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
F - Taxes -14.169 1.081.457 -1,29 65,26 -924.669 70.575.884
2020-02-04 2020-02-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 33.063 1.095.626 3,11
2020-02-04 2020-01-31 4 GBT Global Blood Therapeutics, Inc.
Common Stock
A - Award 579 1.062.563 0,05 36,68 21.238 38.974.811
2020-01-23 2020-01-22 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale X -1.031 1.061.984 -0,10 82,45 -85.011 87.565.785
2020-01-23 2020-01-22 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale X -32.150 1.063.015 -2,94 81,85 -2.631.600 87.011.817
2020-01-23 2020-01-22 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale X -6.819 1.095.165 -0,62 81,01 -552.436 88.723.916
2020-01-23 2020-01-21 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale X -523 1.101.984 -0,05 83,56 -43.703 92.083.436
2020-01-23 2020-01-21 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale X -10.166 1.102.507 -0,91 82,78 -841.562 91.267.734
2020-01-23 2020-01-21 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale X -29.311 1.112.673 -2,57 81,98 -2.402.837 91.213.928
2019-12-17 2019-12-13 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -87.500 0 -100,00
2019-12-17 2019-12-13 4 GBT Global Blood Therapeutics, Inc.
Common Stock
F - Taxes -43.383 1.141.984 -3,66 76,88 -3.335.285 87.795.730
2019-12-17 2019-12-13 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 87.500 1.185.367 7,97
2019-12-09 2019-12-06 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale X -3.716 1.097.867 -0,34 76,15 -282.973 83.602.572
2019-12-09 2019-12-06 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale X -23.152 1.101.583 -2,06 77,72 -1.799.327 85.612.828
2019-12-09 2019-12-06 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale X -6.800 1.124.735 -0,60 76,78 -522.122 86.360.078
2019-12-09 2019-12-06 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale X -6.332 1.131.535 -0,56 75,73 -479.512 85.689.222
2019-12-09 2019-12-05 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale X -6.750 1.137.867 -0,59 75,39 -508.873 85.782.200
2019-12-09 2019-12-05 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale X -8.525 1.144.617 -0,74 74,66 -636.478 85.457.334
2019-12-09 2019-12-05 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale X -996 1.153.142 -0,09 74,08 -73.784 85.424.759
2019-12-09 2019-12-05 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale X -12.442 1.154.138 -1,07 75,35 -937.475 86.961.528
2019-12-09 2019-12-05 4 GBT Global Blood Therapeutics, Inc.
Common Stock
S - Sale X -11.287 1.166.580 -0,96 74,62 -842.262 87.052.883
2019-10-02 2019-09-18 4 PTLA PORTOLA PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 14.812 14.812
2019-10-02 2019-09-18 4 PTLA PORTOLA PHARMACEUTICALS INC
Common Stock
A - Award 8.294 8.294
2019-08-05 2019-08-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -11.250 78.750 -12,50
2019-08-05 2019-08-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -9.750 48.750 -16,67
2019-08-05 2019-08-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -12.062 36.188 -25,00
2019-08-05 2019-08-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
F - Taxes -16.394 1.177.867 -1,37 54,25 -889.374 63.899.285
2019-08-05 2019-08-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 33.062 1.194.261 2,85
2019-07-01 2019-06-27 4 FOLD AMICUS THERAPEUTICS, INC.
Stock Options (right to buy)
A - Award 19.473 19.473
2019-07-01 2019-06-27 4 FOLD AMICUS THERAPEUTICS, INC.
Common Stock
A - Award 6.250 125.145 5,26
2019-04-10 2019-04-08 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -35.000 87.500 -28,57
2019-04-10 2019-04-08 4 GBT Global Blood Therapeutics, Inc.
Common Stock
F - Taxes -17.354 1.161.199 -1,47 58,51 -1.015.383 67.941.753
2019-04-10 2019-04-08 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 35.000 1.178.553 3,06
2019-04-10 2019-01-31 4 GBT Global Blood Therapeutics, Inc.
Common Stock
A - Award 579 1.143.553 0,05 36,68 21.238 41.945.524
2019-02-05 2019-02-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -9.750 58.500 -14,29
2019-02-05 2019-02-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -12.063 48.250 -20,00
2019-02-05 2019-02-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
A - Award 90.000 90.000
2019-02-05 2019-02-01 4 GBT Global Blood Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 145.000 145.000
2019-02-05 2019-02-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
F - Taxes -7.814 1.142.974 -0,68 48,44 -378.510 55.365.661
2019-02-05 2019-02-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 21.813 1.150.788 1,93
2018-08-03 2018-08-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -9.750 68.250 -12,50
2018-08-03 2018-08-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -12.062 60.313 -16,67
2018-08-03 2018-08-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
F - Taxes -10.816 1.128.975 -0,95 43,15 -466.710 48.715.271
2018-08-03 2018-08-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 21.812 1.139.791 1,95
2018-07-17 2018-07-16 4 GBT Global Blood Therapeutics, Inc.
Stock Option (Right to Buy)
M - Exercise -12.194 132.806 -8,41
2018-07-17 2018-07-16 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 12.194 1.117.979 1,10 16,40 199.982 18.334.856
2018-06-11 2018-06-07 4 FOLD AMICUS THERAPEUTICS INC
Stock Options (right to buy)
A - Award 8.912 8.912
2018-06-11 2018-06-07 4 FOLD AMICUS THERAPEUTICS INC
Common Stock
A - Award 3.081 8.895 52,99
2018-03-13 2018-03-09 4 CASC Cascadian Therapeutics, Inc.
Restricted Stock Units
D - Sale to Issuer -13.927 0 -100,00
2018-03-13 2018-03-09 4 CASC Cascadian Therapeutics, Inc.
Common Stock
U - Other -37.394 0 -100,00
2018-02-16 2018-02-14 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -35.000 122.500 -22,22
2018-02-16 2018-02-14 4 GBT Global Blood Therapeutics, Inc.
Common Stock
F - Taxes -17.353 1.105.785 -1,55 62,30 -1.081.092 68.890.406
2018-02-16 2018-02-14 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 35.000 1.123.138 3,22
2018-02-02 2018-02-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
A - Award 78.000 78.000
2018-02-02 2018-02-01 4 GBT Global Blood Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 122.000 122.000
2018-02-02 2018-02-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -12.063 72.375 -14,29
2018-02-02 2018-02-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
F - Taxes -5.981 1.087.142 -0,55 59,60 -356.468 64.793.663
2018-02-02 2018-02-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 12.063 1.093.123 1,12
2018-02-02 2018-01-31 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -35.000 157.500 -18,18
2018-02-02 2018-01-31 4 GBT Global Blood Therapeutics, Inc.
Common Stock
F - Taxes -17.353 1.081.060 -1,58 57,90 -1.004.739 62.593.374
2018-02-02 2018-01-31 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 35.000 1.098.413 3,29
2018-01-26 2018-01-24 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -35.000 192.500 -15,38
2018-01-26 2018-01-24 4 GBT Global Blood Therapeutics, Inc.
Common Stock
F - Taxes -17.354 1.063.413 -1,61 58,15 -1.009.135 61.837.466
2018-01-26 2018-01-24 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 35.000 1.080.767 3,35
2018-01-18 2018-01-16 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -35.000 227.500 -13,33
2018-01-18 2018-01-16 4 GBT Global Blood Therapeutics, Inc.
Common Stock
F - Taxes -17.083 1.045.767 -1,61 52,10 -890.024 54.484.461
2018-01-18 2018-01-16 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 35.000 1.062.850 3,41
2017-09-26 2017-09-24 4 CASC Cascadian Therapeutics, Inc.
Restricted Share Unit (RSU)
M - Exercise -2.375 0 -100,00
2017-09-26 2017-09-24 4 CASC Cascadian Therapeutics, Inc.
Common Stock
F - Taxes -594 37.394 -1,56 3,94 -2.340 147.332
2017-09-26 2017-09-24 4 CASC Cascadian Therapeutics, Inc.
Common Stock
M - Exercise 2.375 37.988 6,67
2017-08-14 2017-08-11 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
A - Award -262.500 262.500 -50,00
2017-08-14 2017-08-11 4 GBT Global Blood Therapeutics, Inc.
Common Stock
D - Sale to Issuer -124.106 1.027.850 -10,77 3,40 -421.340 3.489.551
2017-08-03 2017-08-01 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
M - Exercise -12.062 84.438 -12,50
2017-08-03 2017-08-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
F - Taxes -4.533 1.151.956 -0,39 25,10 -113.778 28.914.096
2017-08-03 2017-08-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
M - Exercise 12.062 1.156.489 1,05
2017-06-27 2017-06-24 4 CASC Cascadian Therapeutics, Inc.
Restricted Share Unit (RSU)
M - Exercise -9.058 0 -100,00
2017-06-27 2017-06-24 4 CASC Cascadian Therapeutics, Inc.
Common Stock
F - Taxes -2.265 35.613 -5,98 3,78 -8.562 134.617
2017-06-27 2017-06-24 4 CASC Cascadian Therapeutics, Inc.
Common Stock
M - Exercise 9.058 37.878 31,43
2017-06-16 2017-06-13 4/A FOLD AMICUS THERAPEUTICS INC
Common Stock
A - Award 5.814 147.814 4,09
2017-06-15 2017-06-13 4 FOLD AMICUS THERAPEUTICS INC
Stock Options (right to buy)
A - Award 16.236 16.236
2017-06-15 2017-06-13 4 FOLD AMICUS THERAPEUTICS INC
Common Stock
A - Award 5.814 5.814
2017-06-13 2017-06-12 4 CASC Cascadian Therapeutics, Inc.
Restricted Share Unit (RSU)
M - Exercise -2.148 0 -100,00
2017-06-13 2017-06-12 4 CASC Cascadian Therapeutics, Inc.
Common Stock
F - Taxes -537 28.820 -1,83 3,34 -1.794 96.259
2017-06-13 2017-06-12 4 CASC Cascadian Therapeutics, Inc.
Common Stock
M - Exercise 2.148 29.357 7,89
2017-06-13 2017-06-09 4 CASC Cascadian Therapeutics, Inc.
Restricted Share Unit (RSU)
A - Award 13.927 13.927
2017-02-14 2017-01-31 5 GBT Global Blood Therapeutics, Inc.
Common Stock
A - Award 1.413 1.144.427 0,12 13,73 19.400 15.712.983
2017-02-14 2016-07-31 5 GBT Global Blood Therapeutics, Inc.
Common Stock
A - Award 378 1.143.014 0,03 15,20 5.746 17.373.813
2017-02-10 2016-06-06 5 CASC Cascadian Therapeutics, Inc.
Restricted Share Unit (RSU)
M - Exercise -2.723 0 -100,00
2017-02-10 2016-06-06 5 CASC Cascadian Therapeutics, Inc.
Common Stock
F - Taxes -681 27.209 -2,44 7,38 -5.026 200.802
2017-02-10 2016-06-06 5 CASC Cascadian Therapeutics, Inc.
Common Stock
M - Exercise 2.723 27.890 10,82
2017-02-03 2017-02-02 4 CASC Cascadian Therapeutics, Inc.
Common Stock
P - Purchase 23.000 27.209 546,45 4,24 97.520 115.366
2017-01-19 2017-01-17 4 GBT Global Blood Therapeutics, Inc.
Stock Option (right to buy)
A - Award 145.000 145.000
2017-01-19 2017-01-17 4 GBT Global Blood Therapeutics, Inc.
Restricted Stock Units
A - Award 96.500 96.500
2016-12-16 2016-07-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
D - Sale to Issuer -24.821 1.139.815 -2,13 3,40 -84.391 3.875.371
2016-06-28 2016-06-24 4 CASC Cascadian Therapeutics, Inc.
Restricted Share Unit (RSU)
A - Award 54.347 54.347
2016-06-13 2016-06-09 4 FOLD AMICUS THERAPEUTICS INC
Stock Options (right to buy)
A - Award 20.000 20.000
2016-02-03 2016-02-01 4 GBT Global Blood Therapeutics, Inc.
Common Stock
A - Award 1.925 1.142.636 0,17 16,09 30.973 18.385.013
2016-01-07 2015-08-17 4 GBT Global Blood Therapeutics, Inc.
Common Stock
P - Purchase 2.500 2.500 20,00 50.000 50.000
2016-01-07 2015-08-17 4 GBT Global Blood Therapeutics, Inc.
Common Stock
P - Purchase 2.500 2.500 20,00 50.000 50.000
2016-01-07 2015-08-17 4 GBT Global Blood Therapeutics, Inc.
Common Stock
P - Purchase 5.000 1.140.711 0,44 20,00 100.000 22.814.220
2015-09-28 2015-09-24 4 ONTY Oncothyreon Inc.
Restricted Share Unit (RSU)
A - Award 14.245 14.245
2015-09-09 2015-09-05 4 ONTY Oncothyreon Inc.
Restricted Share Unit (RSU)
M - Exercise -17.341 0 -100,00
2015-09-09 2015-09-05 4 ONTY Oncothyreon Inc.
Common Stock
F - Taxes -4.336 13.005 -25,00 3,25 -14.092 42.266
2015-09-09 2015-09-05 4 ONTY Oncothyreon Inc.
Common Stock
M - Exercise 17.341 17.341
2015-08-11 3 GBT Global Blood Therapeutics, Inc.
Common Stock
1.157.139
2015-08-11 3 GBT Global Blood Therapeutics, Inc.
Common Stock
1.849.996
2015-08-11 3 GBT Global Blood Therapeutics, Inc.
Common Stock
1.337.139
2015-08-11 3 GBT Global Blood Therapeutics, Inc.
Common Stock
1.234.996
2015-08-11 3 GBT Global Blood Therapeutics, Inc.
Common Stock
1.234.996
2015-08-11 3 GBT Global Blood Therapeutics, Inc.
Common Stock
1.157.139
2015-08-11 3 GBT Global Blood Therapeutics, Inc.
Common Stock
1.849.996
2015-08-11 3 GBT Global Blood Therapeutics, Inc.
Common Stock
1.337.139
2015-08-11 3 GBT Global Blood Therapeutics, Inc.
Common Stock
1.234.996
2015-08-11 3 GBT Global Blood Therapeutics, Inc.
Common Stock
1.234.996
2015-07-14 2015-07-10 4 KBIO KALOBIOS PHARMACEUTICALS INC
Stock Option (right to buy)
A - Award 5.000 5.000
2015-06-16 2015-06-12 4 ONTY Oncothyreon Inc.
Restricted Share Unit (RSU)
A - Award 12.886 12.886
2015-06-12 2015-06-10 4 FOLD AMICUS THERAPEUTICS INC
Stock Options (right to buy)
A - Award 20.000 20.000
2014-12-15 2014-11-25 4 FOLD AMICUS THERAPEUTICS INC
Common Stock
A - Award 32.000 142.000 29,09 7,83 250.637 1.112.201
2014-06-20 2014-06-18 4 KBIO KALOBIOS PHARMACEUTICALS INC
Stock Option (right to buy)
A - Award 20.000 20.000
2014-06-16 2014-06-12 4 FOLD AMICUS THERAPEUTICS INC
Stock Options (right to buy)
A - Award 15.000 15.000
2014-06-10 2014-06-06 4 ONTY Oncothyreon Inc.
Restricted Share Unit (RSU)
A - Award 16.339 16.339
2014-03-12 2014-03-12 4 FOLD AMICUS THERAPEUTICS INC
Common Stock
A - Award 110.000 110.000 2,21 243.100 243.100
2014-01-06 2014-01-02 4 SNTS SANTARUS INC
Stock Options (right to buy)
D - Sale to Issuer -35.000 0 -100,00 26,76 -936.600
2014-01-06 2014-01-02 4 SNTS SANTARUS INC
Stock Options (right to buy)
D - Sale to Issuer -32.500 0 -100,00 25,27 -821.275
2014-01-06 2014-01-02 4 SNTS SANTARUS INC
Stock Options (right to buy)
D - Sale to Issuer -34.500 0 -100,00 26,68 -920.460
2014-01-06 2014-01-02 4 SNTS SANTARUS INC
Stock Options (right to buy)
D - Sale to Issuer -32.000 0 -100,00 28,67 -917.440
2014-01-06 2014-01-02 4 SNTS SANTARUS INC
Stock Options (right to buy)
D - Sale to Issuer -34.500 0 -100,00 28,88 -996.360
2014-01-06 2014-01-02 4 SNTS SANTARUS INC
Stock Options (right to buy)
D - Sale to Issuer -34.500 0 -100,00 25,27 -871.815
2014-01-06 2014-01-02 4 SNTS SANTARUS INC
Stock Options (right to buy)
D - Sale to Issuer -34.500 0 -100,00 10,07 -347.415
2014-01-06 2014-01-02 4 SNTS SANTARUS INC
Common Stock
U - Other -335.500 0 -100,00 32,00 -10.736.000
2013-09-06 2013-09-05 4 ONTY Oncothyreon Inc.
Restricted Share Unit (RSU)
A - Award 17.341 17.341
2013-09-06 3 ONTY Oncothyreon Inc.
Common Stock
0
2013-06-21 2013-06-19 4 MSTX Mast Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 62.451 62.451
2013-06-17 2013-06-13 4 FOLD AMICUS THERAPEUTICS INC
Stock Options (right to buy)
A - Award 15.000 15.000
2013-06-12 2013-06-11 4 SNTS SANTARUS INC
Stock Option (right to buy)
A - Award 34.500 34.500
2013-05-02 2013-04-30 4 KBIO KALOBIOS PHARMACEUTICALS INC
Stock Option (right to buy)
A - Award 15.000 15.000
2012-12-19 2012-12-18 4 SNTS SANTARUS INC
Common Stock
P - Purchase 185.000 335.500 122,92 10,88 2.012.800 3.650.240
2012-09-07 2012-09-05 4 ANX ADVENTRX PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 14.171 14.171
2012-09-07 2012-09-05 4 ANX ADVENTRX PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 18.895 18.895
2012-07-27 2012-07-25 4 ONXX ONYX PHARMACEUTICALS INC
Common Stock
S - Sale X -5.241 77.756 -6,31 73,97 -387.687 5.751.759
2012-06-18 2012-06-13 4 AFFY AFFYMAX INC
Stock Option (Right to Buy)
A - Award 12.000 12.000
2012-06-15 2012-06-13 4 FOLD AMICUS THERAPEUTICS INC
Stock Option (right to buy)
A - Award 30.000 30.000
2012-06-14 2012-06-13 4 SNTS SANTARUS INC
Stock Option (right to buy)
A - Award 34.500 34.500
2012-04-03 2012-04-02 4 ONXX ONYX PHARMACEUTICALS INC
Common Stock
D - Sale to Issuer X -757 82.997 -0,90 36,58 -27.689 3.035.831
2012-04-03 2012-03-30 4 ONXX ONYX PHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 49.700 49.700
2012-04-03 2012-03-30 4 ONXX ONYX PHARMACEUTICALS INC
Common Stock
A - Award 17.150 83.754 25,75
2012-04-03 2012-03-30 4 ONXX ONYX PHARMACEUTICALS INC
Common Stock
A - Award 9.800 66.604 17,25
2012-03-12 2012-03-09 4 SNTS SANTARUS INC
Stock Options (right to buy)
M - Exercise -34.500 0 -100,00
2012-03-12 2012-03-09 4 SNTS SANTARUS INC
Stock Options (right to buy)
M - Exercise -34.500 0 -100,00
2012-03-12 2012-03-09 4 SNTS SANTARUS INC
Stock Options (right to buy)
M - Exercise -34.500 0 -100,00
2012-03-12 2012-03-09 4 SNTS SANTARUS INC
Stock Options (right to buy)
M - Exercise -32.000 0 -100,00
2012-03-12 2012-03-09 4 SNTS SANTARUS INC
Stock Options (right to buy)
M - Exercise -15.000 0 -100,00
2012-03-12 2012-03-09 4 SNTS SANTARUS INC
Common Stock
M - Exercise 34.500 150.500 29,74 2,47 85.215 371.735
2012-03-12 2012-03-09 4 SNTS SANTARUS INC
Common Stock
M - Exercise 34.500 116.000 42,33 2,38 82.110 276.080
2012-03-12 2012-03-09 4 SNTS SANTARUS INC
Common Stock
M - Exercise 32.000 81.500 64,65 1,18 37.760 96.170
2012-03-12 2012-03-09 4 SNTS SANTARUS INC
Common Stock
M - Exercise 34.500 49.500 230,00 2,02 69.690 99.990
2012-03-12 2012-03-09 4 SNTS SANTARUS INC
Common Stock
M - Exercise 15.000 15.000 3,00 45.000 45.000
2012-02-03 2012-02-01 4 ONXX ONYX PHARMACEUTICALS INC
Common Stock
F - Taxes -2.098 56.804 -3,56 41,98 -88.074 2.384.632
2009-03-03 2009-02-27 4 ABIO ARCA biopharma, Inc.
Option to Purchase Common Stock
A - Award 7.500 7.500
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)